Figure 2.

Lowering the diagnostic threshold for hypertension from ≥140/≥90 mm Hg* to ≥130/≥80 mm Hg† increases the number of adults eligible for statins and the number of atherosclerotic cardiovascular disease (ASCVD) events prevented by the 2016 cholesterol guideline, yet the number of statin‐eligible adults is greater with the 2013 cholesterol guideline. By treating more adults and with higher‐dose statins, the 2013 guideline prevents more ASCVD events and induces more diabetes mellitus (lower number needed to harm [NNH]) than the 2016 guideline regardless of the blood pressure threshold for hypertension